Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome: The Puzzle Is Yet to Be Solved

Digestive Diseases and Sciences

Volumn 59, Issue 11, 2014, Pages 2836-2837

  Sachdeva, Sanjeev ^a   Kondala, Raghuram ^a   Dahale, Amol Sonyabapu ^a   Puri, Amarender Singh ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

METHANE; NEOMYCIN; PLACEBO; RIFAXIMIN; ANTIINFECTIVE AGENT; RIFAMYCIN;

ANTIBIOTIC THERAPY; BREATH ANALYSIS; CLINICAL EFFECTIVENESS; CONSTIPATION; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HUMAN; IRRITABLE COLON; LETTER; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SYMPTOM ASSESSMENT; THERAPY EFFECT; TREATMENT RESPONSE; FEMALE; IRRITABLE BOWEL SYNDROME; MALE; PATHOLOGY;

ANTI-INFECTIVE AGENTS; CONSTIPATION; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; RIFAMYCINS;

EID: 84922392394     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3352-7     Document Type: Letter

References (10)

1. Pimental M, Chang C, Chua KS, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci. 2014;59:1278–1285.
2. Pimental M, Chatterjee S, Chow EJ, et al. Neomycin improves constipation predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: sub-analysis of a double blind randomized controlled study. Dig Dis Sci. 2006;51:1297–1301.
3. Low K, Hwang L, Hua J, et al. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010;44:547–550.
4. Pimental M, Lembo A, Chey WD, et al. Rifaximin therapy for the treatment of irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32.
5. Pimental M, Morales W, Lezcano S, Sun-Chuan D, Low K, Yang J. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol. 2009;5:435–442.
6. Attaluri A, Jackson M, Valestin J, et al. Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol. 2010;105:1407–1411.
7. Pimental M, Lin HC, Enayati P, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit, and augments small intestinal contractile activity. Am J Physiol. 2006;290:G1089–G1095.
8. Lee KM, Paik CN, Chung WC, Yang JM, Choi MG. Breath methane positivity is more common and higher in patients with objectively proven delayed transit constipation. Eur J Gastroenterol Hepatol. 2013;25:726–732.
9. Chatterjee S, Park S, Low K, Kong Y, Pimentel M. The degree of breath methane production in IBS correlates with the severity of constipation. Am J Gastroenterol. 2007;102:837–841.
10. Kunkel D, Basseri RJ, Makhani MD, et al. Methane on breath test is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci. 2011;56:1612–1618.